Was the public bidding war over weight loss startup Metsera a sign of things to come in the drug industry? Well, venture capitalist David Schenkein isn’t sure we’ll see many more biotech purchasing battles, but he anticipates it’s just the start of a wave of biotech M&A. “I don’t see M&A slowing down over the next couple of years. If anything, my bet is it’ll be accelerating,” said Schenkein, who co-leads the life sciences investing group at GV, Google’s investment arm. The Metsera deal aside, large pharma companies have bought more than a dozen biotech companies or drug candidates over the last six months.
Read the full article: Veteran Biotech Executive Sees a Wave of M&A Coming — and a Commercial Future for Gene Editing //
Source: https://www.statnews.com/2025/11/21/biotech-mergers-acqusitions-vc-david-schenkein/